News room - Egetis Therapeutics

8 November, 2018 The first patient included in PledPharma’s global Phase III program for PledOx® News English Regulatory IR Optional

26 October, 2018 Nomination Committee appointed for the 2019 Annual General Meeting in PledPharma News English Regulatory IR Optional

23 October, 2018 Interim Report January-September 2018 News English Regulatory MAR Report Interim Q3 IR Optional

28 September, 2018 Study drug for the PledOx® global phase III program delivered News English Regulatory IR Optional

24 September, 2018 Pledpharma announces positive results from the Aladote® proof of principle study News English Regulatory IR Optional

22 August, 2018 Half-Year Report January-June 2018 News English Regulatory MAR Report Interim Q2 IR Optional

15 August, 2018 Delivery of study drug to the PledOx® phase III program is expected in September News English Regulatory IR Optional

25 June, 2018 PledPharma establishes a Scientific Advisory Board for the continued clinical development of Aladote® News English IR Optional

25 June, 2018 Aladote® is concluded as safe in first clinical study – PledPharma aims to apply for Orphan Drug Status in the US News English IR Optional

13 June, 2018 Japanese Medical Agency (PMDA) supports the expansion of the Phase III program for PledOx® to include Japanese patients News English IR Optional

14 May, 2018 PledPharma has completed the recruitment for the clinical trial with Aladote® News English IR Optional

24 April, 2018 Interim Report January-March 2018 News English Regulatory MAR Report Interim Q1 IR Optional

28 March, 2018 PledPharma receives European approval of the composition of matter patent for PledOx® and Aladote® News English IR Optional

22 February, 2018 Year-end Report January-December 2017 News English Report Interim Yearend IR Optional

9 February, 2018 PledOx® shows favorable safety and tolerability profile in the SUNCIST Phase I study in Japanese subjects News English IR Optional

8 February, 2018 Delayed delivery of study drug for the PledOx® phase III program – top-line results still expected during 2020, in line with previous communication News English IR Optional

12 December, 2017 Principal investigator James Dear presents Aladote as a potential new treatment for late stage liver toxicity after paracetamol overdose at Pharmacology conference News English IR Optional

1 December, 2017 First patient included in Phase I study aiming at supporting expansion of global Phase III program for PledOx® to include Asian patients News English IR Optional

20 November, 2017 PledPharma and Solasia enter license agreement to develop and commercialize PledOx® in Asia News English IR Optional

17 November, 2017 PledPharma’s Phase IIb study with PledOx® (PLIANT) published in Acta Oncologica News English IR Optional

16 November, 2017 PledPharma initiates Phase III studies with PledOx® before year end 2017 News English IR Optional

7 November, 2017 PledPharma appoints Yilmaz Mahshid as new CFO News English IR Optional

25 October, 2017 Nomination Committee for the 2018 Annual General Meeting in PledPharma AB News English IR Optional

20 October, 2017 Interim report January - September 2017 News English Report Interim Q3 IR Optional

4 October, 2017 Principal investigator of Aladote® study James Dear presents calmangafodipir as a potential new treatment for late stage liver toxicity after acetaminophen overdose at liver disease conference News English IR Optional

Press releases